Our Work

Upcoming Events

October 27

Location: Washington, DC

Who will be there: Jack Henningfield, Joe Gitchell, Annie Kleykamp, John Pinney, Robyn Gougelet

October 27-30

Location: Boca Raton, FL

Who will be there: Michael Hufford

October 31-November 1

Location: Hyattsville, MD

Who will be there: Jack Henningfield, Ed Cone, August Buchhalter

October 29-November 2

Location: Denver, CO

Who will be there: Annie Kleykamp, Robyn Gougelet

November 2-3

Location: Arlington, VA

Who will be there: August Buchhalter

November 9-13

Location: Miami, FL

Who will be there: Mark Sembower, Deena Battista, Janine Pillitteri

November 14

Location: New York, NY

Who will be there: George Quesnelle

November 15-16

Location: Hyattsville, MD

Who will be there: Annie Kleykamp

November 17

Location: London, England

Who will be there: Joe Gitchell, Robyn Gougelet


Ten years after the Rx-to-OTC switch of nicotine replacement therapy: what have we learned about the benefits and risks of non-prescription availability?

Shiffman S, Sweeney CT

Can consumers self-select for appropriate use of an over-the-counter statin? The Self Evaluation of Lovastatin to Enhance Cholesterol Treatment Study

Shiffman S, Brass EP, Vassil T, Replogle A, Hwang P, Rusche S, Levine JG

Consumer understanding of prescription drug information: An illustration using an antidepressant medication.

Shiffman S, Gerlach KK, Sembower M, Rohay JM

Consumers appropriately self-treat based on labeling for over-the-counter hydrocortisone

Pillitteri J, Ertischek MD, Shiffman S, Ellis CN, Kyle TK, Burton SL


An iterative model for in vitro laboratory assessment of tamper deterrent formulations

Cone EJ, Giordano J, Weingarten B

The new science of abuse-deterrence assessment of pharmaceutical products; FDA proposed guidance and Category 1 laboratory studies

Cone EJ, Buchhalter AR, Henningfield JE, Schnoll S

Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling

Henningfield JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll S, Webster L, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon MA, Abrouk N, Medve R

Do prescription monitoring programs impact state trends in opioid abuse/misuse?

Schnoll S, Fant RV, Reifler LM, Droz D, Bailey JE, Dart RC, Bucher Bartelson B

Epidemiology of stimulant misuse and abuse: implications for future epidemiologic and neuropharmacologic research

Gerlach KK, Dasgupta N, Schnoll S, Henningfield JE

Establishing “abuse-deterrence equivalence” for generic abuse-deterrent opioid formulations: A proposed development framework

Cone EJ, Setnik B

Extreme work requirement of EG-001, an abuse-deterrent, extended-release morphine product, as demonstrated with the ALERRT® Visual Analog Scales.

Cone EJ, Buchhalter AR, Lindhardt K, Elhauge T, Dayno JM

Nonmedical use of prescription ADHD stimulants and preexisting patterns of drug abuse

Sweeney CT, Sembower M, Ertischek MD, Shiffman S, Schnoll S

In the News

Jack Henningfield and Sid Schnoll in National Pain Report: FDA Collaborative Approach Supports Abuse-Deterrent Opioids

View Article »

Learn what Ed Cone said about the FDA Abuse-Deterrent Guidance for Innovator and Generic Opioids

Watch Video »

PinneyAssociates Offers ALERRT® Methodology for In Vitro Assessment of Abuse-Deterrent Formulations

View PDF »

PinneyAssociates Submits Comments to CDC on the 2016 Proposed Opioid Prescribing Guidelines for Chronic Pain